The Hypoxia-inducible Factor 2alpha N-terminal and C-terminal Transactivation Domains Cooperate to Promote Renal Tumorigenesis in Vivo

Overview

Journal Mol Cell Biol

Specialty Cell Biology

Date 2007 Jan 16

PMID 17220275

Citations 115

Authors

Qin Yan

Steven Bartz

Mao Mao

Lianjie Li

William G Kaelin Jr

Affiliations

Soon will be listed here.

Abstract

Hypoxia-inducible factor (HIF) is a heterodimeric transcription factor, consisting of an alpha subunit and a beta subunit, that controls cellular responses to hypoxia. HIFalpha contains two transcriptional activation domains called the N-terminal transactivation domain (NTAD) and the C-terminal transactivation domain (CTAD). HIFalpha is destabilized by prolyl hydroxylation catalyzed by EglN family members. In addition, CTAD function is inhibited by asparagine hydroxylation catalyzed by FIH1. Both hydroxylation reactions are linked to oxygen availability. The von Hippel-Lindau tumor suppressor protein (pVHL) is frequently mutated in kidney cancer and is part of the ubiquitin ligase complex that targets prolyl hydroxylated HIFalpha for destruction. Recent studies suggest that HIF2alpha plays an especially important role in promoting tumor formation by pVHL-defective renal carcinoma cells among the three HIFalpha paralogs. Here we dissected the relative contribution of the two HIF2alpha transactivation domains to hypoxic gene activation and renal carcinogenesis and investigated the regulation of the HIF2alpha CTAD by FIH1. We found that the HIF2alpha NTAD is capable of activating both artificial and naturally occurring HIF-responsive promoters in the absence of the CTAD. Moreover, we found that the HIF2alpha CTAD, in contrast to the HIF1alpha CTAD, is relatively resistant to the inhibitory effects of FIH1 under normoxic conditions and that, perhaps as a result, both the NTAD and CTAD cooperate to promote renal carcinogenesis in vivo.

Citing Articles

Hypoxic Memory Mediates Prolonged Tumor-Intrinsic Type I Interferon Suppression to Promote Breast Cancer Progression.

Iriondo O, Mecenas D, Li Y, Chin C, Thomas A, Moriarty A Cancer Res. 2024; 84(19):3141-3157.

PMID: 38990731 PMC: 11444891. DOI: 10.1158/0008-5472.CAN-23-2028.

Deficiency in PHD2-mediated hydroxylation of HIF2α underlies Pacak-Zhuang syndrome.

Ferens F, Taber C, Stuart S, Hubert M, Tarade D, Lee J Commun Biol. 2024; 7(1):240.

PMID: 38418569 PMC: 10902354. DOI: 10.1038/s42003-024-05904-4.

Decoupling NAD metabolic dependency in chondrosarcoma by targeting the SIRT1-HIF-2α axis.

Suh J, Kim H, Min J, Yeon H, Hemberg M, Scimeca L Cell Rep Med. 2023; 5(1):101342.

PMID: 38128534 PMC: 10829737. DOI: 10.1016/j.xcrm.2023.101342.

The transcription factor HIF2α partakes in the differentiation block of acute myeloid leukemia.

Magliulo D, Simoni M, Caserta C, Fracassi C, Belluschi S, Giannetti K EMBO Mol Med. 2023; 15(11):e17810.

PMID: 37807875 PMC: 10630882. DOI: 10.15252/emmm.202317810.

Genome editing and cancer therapy: handling the hypoxia-responsive pathway as a promising strategy.

Stampone E, Bencivenga D, Capellupo M, Roberti D, Tartaglione I, Perrotta S Cell Mol Life Sci. 2023; 80(8):220.

PMID: 37477829 PMC: 10361942. DOI: 10.1007/s00018-023-04852-2.

References

Semenza G . Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol. 1999; 15:551-78. DOI: 10.1146/annurev.cellbio.15.1.551. View

RYAN H, Lo J, Johnson R . HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J. 1998; 17(11):3005-15. PMC: 1170640. DOI: 10.1093/emboj/17.11.3005. View

Kung A, Wang S, Klco J, Kaelin W, Livingston D . Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med. 2000; 6(12):1335-40. DOI: 10.1038/82146. View

Ebert B, BUNN H . Regulation of transcription by hypoxia requires a multiprotein complex that includes hypoxia-inducible factor 1, an adjacent transcription factor, and p300/CREB binding protein. Mol Cell Biol. 1998; 18(7):4089-96. PMC: 108993. DOI: 10.1128/MCB.18.7.4089. View

Gu Y, Moran S, Hogenesch J, Wartman L, Bradfield C . Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. Gene Expr. 1998; 7(3):205-13. PMC: 6151950. View

OROURKE J, Tian Y, Ratcliffe P, Pugh C . Oxygen-regulated and transactivating domains in endothelial PAS protein 1: comparison with hypoxia-inducible factor-1alpha. J Biol Chem. 1999; 274(4):2060-71. DOI: 10.1074/jbc.274.4.2060. View

Ema M, Hirota K, Mimura J, Abe H, Yodoi J, Sogawa K . Molecular mechanisms of transcription activation by HLF and HIF1alpha in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. EMBO J. 1999; 18(7):1905-14. PMC: 1171276. DOI: 10.1093/emboj/18.7.1905. View

Tang N, Wang L, Esko J, Giordano F, Huang Y, Gerber H . Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell. 2004; 6(5):485-95. DOI: 10.1016/j.ccr.2004.09.026. View

Covello K, Simon M, Keith B . Targeted replacement of hypoxia-inducible factor-1alpha by a hypoxia-inducible factor-2alpha knock-in allele promotes tumor growth. Cancer Res. 2005; 65(6):2277-86. DOI: 10.1158/0008-5472.CAN-04-3246. View

10.

Rankin E, Higgins D, Walisser J, Johnson R, Bradfield C, Haase V . Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice. Mol Cell Biol. 2005; 25(8):3163-72. PMC: 1069599. DOI: 10.1128/MCB.25.8.3163-3172.2005. View

11.

Raval R, Lau K, Tran M, Sowter H, Mandriota S, Li J . Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol. 2005; 25(13):5675-86. PMC: 1157001. DOI: 10.1128/MCB.25.13.5675-5686.2005. View

12.

Dayan F, Roux D, Brahimi-Horn M, Pouyssegur J, Mazure N . The oxygen sensor factor-inhibiting hypoxia-inducible factor-1 controls expression of distinct genes through the bifunctional transcriptional character of hypoxia-inducible factor-1alpha. Cancer Res. 2006; 66(7):3688-98. DOI: 10.1158/0008-5472.CAN-05-4564. View

13.

Hughes T, Mao M, Jones A, Burchard J, Marton M, Shannon K . Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer. Nat Biotechnol. 2001; 19(4):342-7. DOI: 10.1038/86730. View

14.

Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M . HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001; 292(5516):464-8. DOI: 10.1126/science.1059817. View

15.

Jaakkola P, Mole D, Tian Y, Wilson M, Gielbert J, Gaskell S . Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001; 292(5516):468-72. DOI: 10.1126/science.1059796. View

16.

Yu F, White S, Zhao Q, Lee F . HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci U S A. 2001; 98(17):9630-5. PMC: 55503. DOI: 10.1073/pnas.181341498. View

17.

Epstein A, Gleadle J, McNeill L, Hewitson K, ORourke J, Mole D . C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 2001; 107(1):43-54. DOI: 10.1016/s0092-8674(01)00507-4. View

18.

Mahon P, Hirota K, Semenza G . FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 2001; 15(20):2675-86. PMC: 312814. DOI: 10.1101/gad.924501. View

19.

Bruick R, McKnight S . A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 2001; 294(5545):1337-40. DOI: 10.1126/science.1066373. View

20.

Lando D, Peet D, Whelan D, Gorman J, Whitelaw M . Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science. 2002; 295(5556):858-61. DOI: 10.1126/science.1068592. View